Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.

Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.